Market Place
Sourcing Support
All News #Library
Biotech
Tyra Biosciences Reveals 2025 Financials And Recent Achievements
02 Mar 2026 //
PR NEWSWIRE
Tyra Biosciences Presents Posters At 2026 ASCO Genitourinary
24 Feb 2026 //
PR NEWSWIRE BIO
Tyra Biosciences To Participate In Upcoming Investor Conferences
19 Feb 2026 //
PR NEWSWIRE
Tyra Biosciences To Participate In Investor Conferences
13 Nov 2025 //
PR NEWSWIRE
Tyra Biosciences Reveals Q3 2025 Financial Results
05 Nov 2025 //
PR NEWSWIRE
Tyra Biosciences Doses 1st Child in Ph2 Pediatric Achondroplasia
21 Aug 2025 //
PR NEWSWIRE
Tyra Biosciences Reports Q2 2025 Financial Results
14 Aug 2025 //
PR NEWSWIRE
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300
30 Jun 2025 //
PR NEWSWIRE
Tyra Biosciences Reports Q1 2025 Financial Results
08 May 2025 //
PR NEWSWIRE
Tyra Biosciences Reports 2024 Financial Results and Highlights
27 Mar 2025 //
PR NEWSWIRE
Tyra Bio Announces Appointment of Adele to Board of Directors
29 Jan 2025 //
PR NEWSWIRE
Tyra Gets IND Clearance for TYRA-300 in Bladder Cancer Phase 2
10 Jan 2025 //
PR NEWSWIRE
Tyra Biosciences Reports Q3 2024 Financial Results & Highlights
07 Nov 2024 //
PR NEWSWIRE
Tyra Biosciences Gets IND Clearance for Pediatric BEACH301 Study
28 Oct 2024 //
PR NEWSWIRE
Tyra Bio Reports Data For TYRA-300 In Metastatic Urothelial Cancer
24 Oct 2024 //
PR NEWSWIRE
Tyra Biosciences To Host Call On Interim Data Of TYRA-300 On Oct 25
23 Oct 2024 //
PR NEWSWIRE
Tyra Present on TYRA-300 at 36th EORTC-AACR Symposium
11 Oct 2024 //
PR NEWSWIRE
Tyra Biosciences Appoints Doug, M.D., As Chief Medical Officer
10 Sep 2024 //
PR NEWSWIRE
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
07 Aug 2024 //
PR NEWSWIRE
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
09 May 2024 //
PR NEWSWIRE
Tyra Biosciences Reports4Q FYR 2023 & Highlights
19 Mar 2024 //
PR NEWSWIRE
Tyra Biosciences to Present at Upcoming Investor Conferences
27 Feb 2024 //
PR NEWSWIRE
Tyra Biosciences Doses First Patient with TYRA-200
22 Dec 2023 //
PR NEWSWIRE
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia
21 Sep 2023 //
PR NEWSWIRE
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
10 Aug 2023 //
PR NEWSWIRE
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
04 May 2023 //
PR NEWSWIRE
Tyra Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
22 Mar 2023 //
PR NEWSWIRE
Tyra Biosciences Expands Development of TYRA-300
01 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.